NervGen Pharma Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for NervGen Pharma stock has a target of 18, which predicts an increase of 363.92% from the current stock price of 3.88.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$18	$18	$18	$18
Change	+363.92%	+363.92%	+363.92%	+363.92%

Analyst Ratings

According to 1 stock analyst, the rating for NervGen Pharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Apr '26
Strong Buy	1
Buy	0
Hold	0
Sell	0
Strong Sell	0
Total	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Initiates $18	Strong Buy	Initiates	$18	+363.92%	Apr 27, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-0.30

from -0.61

EPS Next Year

-0.25

from -0.30

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-	-
EPS	-0.32	-0.39	-0.38	-0.36	-0.61	-0.30	-0.25
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	3	2

Financial currency is CAD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2026	2027
High	-0.22	-0.26
Avg	-0.30	-0.25
Low	-0.37	-0.25

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.